News
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss. Latest U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback